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Arterial thromboembolic events and their ischemic complications give rise to a variety of vasoocculusive disorders such as unstable angina, myocardial infarction, stroke, or peripheral arterial diseases.
1) As such diseases still remain the leading cause of human morbidity and mortality, 2) new antithrombotic therapeutic agents are needed.
Serotonin is accumulated into platelets, stored, and later released from platelets activated by collagen, norepinephrine (NE), thromboxan A 2 (TXA 2 ), adenosine diphosphate (ADP) and other endogenous products. Serotonin only weakly induces platelet aggregation, but synergistically potentiates the effects of the above vasoactive and platelet aggregative substances. 3) Since these activities have been demonstrated to be mediated through the serotonin 2 (5-HT 2 ) receptor, 4) 5-HT 2 receptor selective antagonists are expected to be useful in the treatment of peripheral circulatory disorders involving vasoconstriction and platelet aggregation.
5)
The 5-HT 2 receptor antagonist ketanserin (1, Fig. 1 ) has been shown to be beneficial in the treatment of some circulatory diseases. 4a,6) It is well known that this compound has not only potent 5-HT 2 receptor antagonist activity but also considerable a 1 -adrenoceptor blocking activity which has been confirmed to be responsible for the blood pressure reduction.
7) Due to adverse effects such as hypotension based on a 1 -adrenoceptor blocking activity, compounds with less potent a 1 blocking activity are preferable. The selective 5-HT 2 receptor antagonist, sarpogrelate (2a), was recently reported as a therapeutic agent for treatment of peripheral circulatory disturbance. 8) We are interested in preparing agents with new pharmacological profiles based on utilization of unique skeletons. Previously, we reported the structure-activity relationships (SAR) of pyrrolo[2, 3-c] azepine derivatives containing a unique bicyclic ring found in certain marine sponges.
9) The ring system was found to be a useful component in eliciting a 1 -and/or 5-HT 2 -receptor antagonist activities, which were markedly affected by the nature of the functional group at the 4-position of the pyrroloazepine ring. Certain compounds, especially (E)-1-[4-[4-(4-fluorobenzoyl)piperidino]butyl]-4-hydroxyimino-7-methyl-1,4,5,6,7,8-hexahydropyrrolo[2, 3-c] azepin-8-one (3, SUN9221), were potent antihypertensive agents with potent a 1 -and 5-HT 2 -receptor antagonist activities. These results suggested that further modification of this ring may produce a selective 5-HT 2 receptor antagonist, and therefore we synthesized and evaluated pyrrolo [3,2-c] azepine derivatives (Fig. 2, I ) and related compounds.
In this paper, we describe the SAR within a series of these compounds that led to the discovery of SUN C5174 (compound (Ϫ)-18a), a potent and selective 5-HT 2 receptor antagonist.
Chemistry Synthetic pathways for preparation of the key intermediates (7, 12 and 13) are shown in Chart 1. (1-Substituted)-3-pyrrolecarboxylic acids (4) were condensed with b-alanine benzyl ester p-toluenesulfonate in the presence of diethyl phosphorocyanidate (DEPC), 10) followed by hydrogenolysis of the benzyl group affording 3-(3-pyrrolecarboxamido)propionic acids (6) in good yields. Cyclization of the resultant 6 with 80% polyphosphoric acid (PPA) at 100°C produced predominantly pyrrolo [3,2-c] azepine compounds (7) over pyrrolo [3,4-c] azepine compounds (8) in the range of approximately 2.3 : 1, and whose structures were determined by comparison of NMR data of both compounds (method A). 11) Compounds 7c and 7d were prepared by alkylation of 7a in high yields (method B). Subsequently, the reaction of 7 with a-bromo-w-chloroalkane in the presence of tert-BuOK afforded the w-chloro derivatives (12), but yields were poor (method C). As this route was not satisfactory, a more expedient route was investigated. Condensation of 4 with N-substituted b-alanine ester derivative (9) , followed by alkaline hydrolysis of the ester group and cyclization with a mixture of methanesulfonic acid and P 2 O 5 , directly afforded predominantly the pyrrolo [3,2-c] azepine derivatives (12) in better yields accompanied by small amounts of isomeric 13 (method D).
The target compounds indicated in Tables 1-4 were synthesized as outlined in Charts 2-3. The w-chloro derivatives (12) were reacted with the appropriate amine in the presence of base (K 2 CO 3 or NaHCO 3 ) and NaI to give the 8-aminoalkyl compounds (14) in good yields (method E). As introduction of the chloroethyl group into 7b by method C was unsuccessful, an alternative approach was adopted for preparation of 14n. Direct introduction of an aminoethyl moiety into the 5-position of 7b using 1-(2-chloroethyl)-4-(4-fluorophenyl)piperazine in the presence of NaH gave 14n in 18% yield (method F). Reduction of 14 with NaBH 4 afforded the desired 8-hydroxy compounds (18) (method G). Compound 18b, with a carbonyl group in the amino moiety at the 5-position, was prepared by initial reduction of 12 and subsequent replacement of chlorine atom by amination (method H) (Chart 2). The derivatives (15, 16, 19 and 20) with various groups at the 8-position were synthesized from 14a and 18a. Treatment of 14a with hydroxylamine hy-drochloride in basic medium afforded exclusively the (E)-oxime (15) accompanied by a very small amount of the (Z)-oxime (15Ј), which could be easily separated by column chromatography (method I).
12) Thioacetal compound (16) was obtained by reaction of 14a with ethanedithiol and boron trifluoride etherate (method J). Compound 18a was dehydrated with hydrogen chloride in CHCl 3 to give the 7,8-unsaturated compound (19) (method K), which was reduced by catalytic hydrogenation on Pd on carbon to give the 8-methylene compound (20) (method L). The isomeric pyrrolo [3,4-c] azepine derivatives (21 and 22) were prepared from 13a in a manner similar to preparation of 14a and 18a, respectively (methods M, N) (Chart 3).
Optical resolution of 18a was performed by diastereomeric salt formation with optically active tartaric acid, followed by fractional recrystallization. Treatment of the resolved-amine tartaric acid salts with aqueous NaOH and subsequent recrystallization produced free bases, (Ϫ)-18a and (ϩ)-18a (Chart 4). The enantiomeric purities of (Ϫ)-18a and (ϩ)-18a were over 99% ee, as determined by HPLC using a chiral column. The absolute configuration of (Ϫ)-18a was established as 8S on the basis of X-ray crystallographic analysis of (Ϫ)-18a · L-(ϩ)-tartaric acid salt (Fig. 3) .
The chemical structures of the synthesized compounds were confirmed from spectroscopic data (IR, 1 H-NMR, MS) and elemental analyses.
Results and Discussion
It has been reported that the contractions induced by serotonin and NE in the isolated mesenteric artery and aorta of the guinea pig are mainly caused by activation of 5-HT 2 receptors and a 1 -adrenergic receptors, respectively.
13) Therefore, antagonistic effects of compounds on 5-HT 2 receptors and a 1 -adrenergic receptors were evaluated in terms of the ability to block 10 Ϫ5 M serotonin-induced contractions and 10 Ϫ5 M NE-induced contractions of isolated guinea pig arter-ies, respectively. Details concerning the test methods are described in the Experimental Section. Initially, we investigated the influence of various groups at the 8-position of 1-methylpyrrolo [3,2-c] azepine derivatives, as shown in Table 1 . 5-HT 2 receptor antagonist activity and selectivity were largely affected by the nature of this group. While a carbonyl derivative (14a) and a (E)-hydroxyimino compound (15) exhibited only weak 5-HT 2 receptor antagonist activity, the hydroxy compound (18a) showed very potent activity. Compounds 16 and 19 had potent 5-HT 2 receptor antagonist activity comparable to that of 18a, but at the expense of higher a 1 blocking and D 2 receptor binding activities. Furthermore, methylene compound (20) exhibited the same or slightly more potent 5-HT 2 receptor antagonist activity, but had low selectivity since a 1 blocking activity was rather more potent than that of 18a. The hydroxy group must be an important factor for manifestation of the potent and selective 5-HT 2 receptor antagonist activity.
Subsequently, the effects of various amines were examined with compounds containing a hydroxy group at the 8-position. As shown in Table 2 , the amine moieties markedly affected the 5-HT 2 blocking activity. The compounds with a "ketanserin side chain" (18b) and 4-phenylpiperidine (18c) did not exhibit potent activity. Compound 18d, which has a piperazine moiety instead of piperidine, showed improved potency, but the selectivity was not sufficient. The effects of substituents on the benzene ring on activity were further explored in a piperazine series. 4-Fluoro substitution (18a) led to marked improvement of both 5-HT 2 receptor antagonist activity and selectivity, whereas 2-fluoro (18e) or 3-fluoro (18f) substitution diminished the activity, in comparison with the unsubstituted compound 18d. 4-Chloro (18g) and 4-hydroxy (18h) compounds exhibited less potent activity than the 4-fluoro compound (18a), and comparably weak a 1 blocking and D 2 receptor binding activities as the 4-fluoro compound. The results with compounds 18a and 18d-h suggested that the presence of a substituent in the 4-position of the benzene ring was important for suppressing a 1 blocking activity and D 2 receptor binding affinity. Both 4-nitro (18i) and 4-methoxy (18j) compounds showed negligible 5-HT 2 receptor antagonist activity. These observations suggested that the 5-HT 2 receptor antagonist activity was influenced by both the electronic and steric effects of the substituents at the 4-position. Larger groups such as methoxy and nitro groups at the 4-position interfere with the interaction, and serve to reduce activity. Replacement of the phenyl group with other groups such as a benzhydryl (18k), 2-pyrimidinyl (18l) and 3-(1,2-benzisothiazolyl) group (18m) markedly diminished activity.
The next step was optimization of the alkylene chain length (n) at the 5-position and the substituent at the 1-position of the pyrrolo[3,2-c]azepine skeleton, whilst maintaining the optimal amine moiety of 18a. The results of this study are summarized in Table 3 . Alteration of the alkyl chain between the 5-position of pyrrolo [3,2-c] azepine and the 4-(4-fluorophenyl)piperazine moiety from propylene (18a) to either ethylene (18n) or tetramethylene (18o), reduced the 5-HT 2 receptor antagonist activity by more than 10-fold. The length of the alkyl side chain was critical for selectivity against a 1 blocking activity as well as 5-HT 2 receptor antagonist activity, and was optimal with nϭ3.
Subsequently, the effects of the substituent at the 1-position were examined. Substitution of the methyl group by larger groups such as an ethyl (18p), benzyl (18q) and phenyl (18r) groups resulted in a decrease in the 5-HT 2 receptor antagonist activity, suggesting some steric effects around this position. The best result was obtained with compound 18a with the methyl group at the 1-position. We prepared the isomeric pyrrolo [3,4-c] azepine analog of 18a in order to clarify the pharmacological significance of the pyrrolo[3,2-c]azepine skeleton. As shown in Table 4 , the isomeric compound 22 exhibited less than one tenth of the 5-HT 2 receptor antagonist activity of the corresponding compound 18a, indicating that combination of the pyrrolo [3,2-c] azepine skeleton and the 8-hydroxy group of 18a is important for manifestation of the potent 5-HT 2 receptor antagonist activity.
Consequently, we selected compound 18a for further studies. Compound 18a was a racemic compound possessing an asymmetric center at the 8-position in the pyrroloazepine ring. Since Pfeiffer's rule states that highly potent chiral compounds display a large difference in potency between their enantiomers, 14) we resolved 18a via a diastereomeric salt to separate (ϩ)-18a and (Ϫ)-18a, and subsequently elucidated their pharmacological properties. In the experiment using isolated guinea pig arteries, the 5-HT 2 receptor antagonist activity of 18a was found to reside primarily in (Ϫ)-18a, which was about 14-fold more potent than that of (ϩ)-18a. In contrast, the a 1 blocking activity of (Ϫ)-18a was equivalent to or less than that of (ϩ)-18a (Table 5 ). (Ϫ)-18a displayed high 5-HT 2 receptor binding affinity (IC 50 ϭ4.26 nM), which was 60-fold or more than 100-fold higher than its affinity for a 1 receptors (IC 50 ϭ254 nM) or 5-HT 1A receptors (IC 50 ϭ480 nM) respectively, and more than 400-fold higher for other receptors such as a 2 (IC 50 ϭ2380 nM), b (IC 50 Ͼ10000 nM), D 2 (IC 50 ϭ2380 nM), muscarinic cholinergic (mACh) (IC 50 Ͼ 10000 nM), H 1 (IC 50 ϭ1730 nM) and H 2 (IC 50 ϭ7790 nM) receptors in receptor binding assays.
In human and canine platelet-rich plasma (PRP), collagenor ADP-induced platelet aggregation potentiated by serotonin was markedly inhibited by (Ϫ)-18a (IC 50 ϭ6.5-16 nM) ( Table 6 ). This antiplatelet aggregation effect by (Ϫ)-18a was more than 20-fold stronger than that by (ϩ)-18a, and more than 2-and 100-fold stronger than those by ketanserin and sarpogrelate, respectively.
Next, we evaluated both enantiomers in an in vivo study. In the acute pulmonary thromboembolic death model in mice, (Ϫ)-18a (0.03 to 1 mg/kg) inhibited the mortality in a dosedependent manner by oral administration before induction of platelet aggregation, and its inhibitory effect was significant at doses of 0.3 mg/kg or higher (Fig. 4) . In addition, (ϩ)-18a and ketanserin significantly inhibited mortality at 3 and 1 mg/ kg, respectively. In contrast, sarpogrelate showed no significant inhibitory effect even at 30 mg/kg. From the results of in vitro and in vivo experiments, it was suggested that (Ϫ)-18a showed much more potent and selective 5-HT 2 receptor antagonist activity than (ϩ)-18a.
In conclusion, several 5-aminoalkylpyrrolo[3,2-c]azepine derivatives showed potent 5-HT 2 receptor antagonist activity.
Vol. 48, No. 5 Table 6 . Antiplatelet Aggregation Effects of (Ϫ)-18a and Reference Drugs in Canine and Human Platelet-rich Plasma Compound (Ϫ)-18a (SUN C5174) is currently undergoing clinical evaluation for treatment of peripheral circulatory diseases. Further pharmacological evaluation of (Ϫ)-18a will be reported elsewhere.
Experimental
Melting points were determined in open capillaries with a Büchi 535 digital melting point apparatus, and are uncorrected. The 1 H-NMR spectra were recorded on a JEOL JNM-GX270 or Brucker ARX 400 FT NMR spectrometer, and the chemical shifts were expressed in d (ppm) values with tetramethylsilane as an internal standard. IR spectra were recorded on a PerkinElmer 1640 instrument. High resolution fast atom bombardment mass spectra (HR-FAB-MS) were measured on a JEOL JMS-HX110A instrument. Elemental analyses were performed on a Perkin-Elmer 240B elemental analyzer. Optical rotations were measured on a JASCO DIP-360 polarimeter.
In general, all organic extracts were dried over anhydrous sodium sulfate and the solvent was removed with a rotary evaporator under reduced pressure. Analytical TLC was carried out using Silica gel 60 F 254 plates (Merck Art 5715). Column chromatography was performed on Silica gel 60 (Merck Art 9385, 230-400 mesh).
The following known materials were prepared as described in the literature: methyl pyrrole-3-carboxylate; 15) pyrrole-3-carboxylic acid; 15b) 1-phenyl-1H-pyrrole-3-carboxylic acid; 16) 1-(4-hydroxyphenyl)piperazine hydrobromide; 17) 1-(1,2-benzisothiazol-3-yl)piperazine; 18) 1-(2-chloroethyl)-4-(4-fluorophenyl)piperazine. 19) 1-(3-Fluorophenyl)piperazine was prepared according to a procedure similar to that described in the literature.
17)
Methyl 1-Methyl-1H-pyrrole-3-carboxylate The method of Guida and Mathre 20) was employed with minor modification. Potassium tert-butoxide (49.8 g, 444 mmol) and 18-crown-6 (7.82 g, 29.6 mmol) were added successively to a stirred solution of methyl pyrrole-3-carboxylate (37.0 g, 296 mmol) in Et 2 O (370 ml) at 0°C. To the resultant suspension was added dropwise a solution of MeI (84.0 g, 592 mmol) in Et 2 O (30 ml) under vigorous stirring and ice-cooling, followed by stirring at room temperature for 1 h. The reaction mixture was poured into half-saturated NaCl (200 ml), and the layers were separated. The aqueous layer was extracted with Et 2 O (2ϫ50 ml). The combined organic layers were washed with brine, dried, and evaporated to give an oil, which was distilled to afford the title compound 
1-Methyl-1H-pyrrole-3-carboxylic Acid (4b)
A mixture of methyl 1-methyl-1H-pyrrole-3-carboxylate (13.0 g, 93.4 mmol), 1 N NaOH (156 ml) and MeOH (156 ml) was stirred under reflux for 6 h. The reaction mixture was concentrated, and the residue was partitioned between water and Et 2 O (150 ml each). The aqueous layer was acidified with 6 N HCl and extracted with EtOAc (3ϫ150 ml). The combined extracts were washed with brine (150 ml), dried, and concentrated to give a solid which was recrystallized from EtOAc-diisopropyl ether (IPE) to afford 4b (9.29 g, 79%) as pale brown crystals, mp 144.0-145.5°C (lit., 21) 145.0-145.5°C). IR (KBr): 3300-2200, 1671 cm Ethyl 3-(3-Chloropropyl)aminopropionate Hydrochloride (9) 3-Chloropropylamine hydrochloride (130 g, 1 mol) was added to a stirred solution of 5 N NaOH (200 ml) at 0°C. To the resultant solution was added N,Ndimethylformamide (DMF) (400 ml) and ethyl acrylate (120 g, 1.20 mol) successively below 10°C. After stirring at room temperature for 16 h, the reaction mixture was poured into water (600 ml) and then extracted with EtOAc (4ϫ200 ml). The combined extracts were washed with water (3ϫ 200 ml) and brine (200 ml), dried, and concentrated to afford a yellow oil (195 g). 4 N hydrogen chloride solution in EtOAc (252 ml) was added dropwise to a solution of the resultant oil in EtOAc (974 ml) below 15°C under stirring, and stirring was continued at 0°C for 30 min. The precipitates were filtered and washed twice with EtOAc to give 9 (148 g, 64%), mp 138. 1 mmol) in DMF (400 ml) at 0°C were added dropwise and successively a solution of DEPC (14.5 g, 89.1 mmol) in DMF (50 ml) and a solution of Et 3 N (18.0 g, 178 mmol) in DMF (50 ml). After stirring at room temperature for 16 h, the reaction mixture was concentrated. The residue was dissolved in EtOAc-benzene (2 : 1 v/v, 600 ml), washed successively with half-saturated K 2 CO 3 , water, 10% citric acid, water and brine (300 ml each). The organic layer was dried and concentrated to give a brown solid, which was recrystallized from EtOAchexane to afford 5b (19 A suspension of 5b (19.0 g, 66.4 mmol) and 5% Pd-C (1.90 g, 10% wt eq) in tetrahydrofuran (THF) (500 ml) was vigorously stirred under an atmos- A mixture of 6b (11.0 g, 56.1 mmol) and approximately 80% PPA (550 g) was mechanically stirred at 100°C for 1 h and then 120°C for 10 min. The reaction mixture was poured into ice-water, and the pH of the solution was adjusted to 4 with K 2 CO 3 . The resultant solution was extracted with CHCl 3 (2ϫ1 l, 2ϫ500 ml). The extracts were washed with brine, dried, and concentrated to give a solid, which contained 7b and 8b. The mixture was subjected to column chromatography (eluent, EtOAc : MeOHϭ97 : 3, then CHCl 3 : MeOHϭ19 : 1) to give 7b (6.29 g, 63%) from the first fraction. The second fraction yielded 8b (2.58 g, 26% Compound 7d was prepared in a similar manner to that described for 7c, and used immediately in the next step. 7d: 93% yield, colorless crystals, mp 170.5-171.5°C (EtOAc-hexane). 5 mmol) at 0°C followed by stirring at the same temperature for 1 h. A solution of 1-bromo-3-chloropropane (5.90 g, 37.5 mmol) in THF (40 ml) was added dropwise to the reaction mixture at 0°C and stirring was continued at room temperature for 93 h. An aqueous solution of citric acid (1.58 g, 8.2 mmol) was then added, and the mixture was concentrated. The residue was diluted with water (100 ml), and extracted with CHCl 3 (2ϫ100 ml). The combined extracts were washed with brine, dried, and concentrated to give an oil, which was purified by column chromatography (eluent, EtOAc : hexaneϭ2 : 1) to afford 12a (628 mg, 33%), which was used immediately in the next step. A pure sample was obtained by recrystallization, mp 116. Compounds 12b-d were prepared in a similar manner to that described for 7c, and was used without further purification. 12b: 49% yield, colorless Chloropropyl)-1-methyl-1,4,5,6,7,8-hexahydropyrrolo[3,2-c]azepine-4,8-dione (12a) and 5-(3-Chloropropyl)-2-methyl-2,4,5,6,7,8-hexahydropyrrolo[3,4-c]azepine-4,8-dione (13a) To a stirred solution of 4b (12.5 g, 100 mmol) and 9 (27.6 g, 120 mmol) in CH 2 Cl 2 (450 ml) at 0°C were added successively a solution of Et 3 N (12.1 g, 120 mmol) in CH 2 Cl 2 (50 ml), powdered 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSCD · HCl) (23.0 g, 120 mmol) and powdered 4-dimethylaminopyridine (4-DMAP) (2.93 g, 24 mmol). After sirring at room temperature for 5 h, the reaction mixture was washed sequentially with water, 1 N HCl, water, half-saturated NaHCO 3 , water and brine (250 ml each), dried, and concentrated. The residue was purified by column chromatography (eluent, EtOAc : hexaneϭ1 : 1) to afford 10a (26 To a stirred solution of ester 10a (1.50 g, 5 mmol) in THF (2.6 ml) was added dropwise 2 N NaOH (2.6 ml, 5.2 mmol) under ice-cooling followed by stirring at room temperature for 30 min. The resultant solution was acidified (pH ca. 3) with 6 N HCl under ice-cooling, and then extracted with CH 2 Cl 2 (3ϫ50 ml). The combined extracts were washed with brine, dried, and concentrated to afford crude carboxylic acid 11a (1.36 g). This material was immediately used in the next step without further purification.
To crude 11a (1.36 g) was added a solution (5.82 g) which was prepared by stirring a mixture of P 2 O 5 and methanesulfonic acid (1 : 6.1 w/w) at 90°C until homogeneity (approximately 2 h) in another vessel, and the resultant mixture was stirred at 90°C for 30 min. The reaction mixture was poured into ice-water, and extracted with CHCl 3 (3ϫ100 ml). The organic extracts were washed with brine, dried, and concentrated to give a solid, which contained 12a and 13a. The mixture was subjected to column chromatography (eluent, EtOAc) to give 12a (945 mg, 74%) as colorless crystals from the first fraction. The second fraction yielded 13a (107 mg, 8.4%). 12a: Physical data were identical with those of the compound prepared by method C. Compounds 12e and 13e were synthesized from 4c in a similar manner described for 12a and 13a, and used immediately in the next step. 12e: 51% overall yield, mp 97.0-98.5°C (EtOAc-hexane), colorless crystals. 3 .6 mmol), K 2 CO 3 (498 mg, 3.6 mmol) and NaI (720 mg, 4.8 mmol) in CH 3 CN (30 ml) was stirred under reflux for 38 h. After the solvent was removed, the residue was diluted with half-saturated K 2 CO 3 (50 ml), and then extracted with CHCl 3 (2ϫ100 ml). The combined extracts were washed with brine, dried, and concentrated to give an oil, which was purified by column chromatography (eluent, EtOAc : MeOHϭ9 : 1) to afford 14a ( 14a, except that in the syntheses of 14c, 14i, 14k and 14m, amine (1 eq) and NaHCO 3 (2 eq) were used instead of amine (1.5 eq) and K 2 CO 3 (1.5 eq): in the syntheses of 14e and 14g, amine hydrochloride (1 eq) and NaHCO 3 (4 eq) were used: in the syntheses of 14f and 14h, amine hydrobromide (1 eq) and NaHCO 3 (4 eq) were used: in the syntheses of 14j and 14l, amine dihydrochloride (1 eq) and NaHCO 3 (6 eq) were used. These compounds were immediately transformed to the corresponding alcohol 18 by method G. 1,4,5,6,7,8-hexahydropyrrolo[3,2-c]azepine-4,8-dione (14n) To a stirred suspension of NaH (1.92 g of a 60% oil dispersion, 48 mmol) in DMF (100 ml) was added a solution of 7b (7.13 g, 40 mmol) in DMF (150 ml) at 0°C over a period of 30 min. The mixture was stirred at 0°C for 30 min and at room temperature for 90 min, and then cooled again to 0°C. A solution of 1-(2-chloroethyl)-4-(4-fluorophenyl)piperazine (14.6 g, 60 mmol) in DMF (150 ml) was added to the mixture over a period of 30 min, and stirring was continued at room temperature for 16 h. The title compound 14n (2.77 g, 18%) was obtained as a yellow oil by the same work-up and purification procedure as described for the preparation of 14a. IR (film): 1652, 1626 cm To a stirred solution of ketone 14a (797 mg, 2 mmol) in EtOH (30 ml) was added portionwise NaBH 4 (757 mg, 20 mmol) at 0°C, and stirring was continued at 0°C for 1 h and at room temperature for 16 h. Water (20 ml) was added, and the resultant mixture was stirred at room temperature for 1 h. After the solvent was removed, the residue was diluted with brine (100 ml) and then extracted with CHCl 3 (3ϫ100 ml). The combined extracts were washed with brine, dried, and concentrated. The residue was purified by column chromatography (eluent, EtOAc : MeOHϭ4 : 1) to afford 18a (710 mg, 89%) as colorless crystals. Compound 18n was synthesized similarly from 14n. Compounds 18c-m and 18o-r were prepared by amination of chloride 12 (method E) and successive reduction of crude 14 (method G) in a similar manner to that described above. The physical data for compounds 18a and 18c-r are listed in Table 7 . methyl-1,4,5,6,7,8-hexahydropyrrolo[3,2-c] azepin-4-one (18b) To a stirred suspension of ketone 12a (255 mg, 1 mmol) in EtOH (10 ml) was added portionwise NaBH 4 (85 mg, 2.25 mmol) at 0°C, followed by stirring at room temperature for 6 h. The work-up was performed in a similar manner to that described in method G to give crude 17 (256 mg) as a colorless solid. This material was sufficiently pure to be used without further purification in the next step. A pure sample was obtained by recrystallization from EtOAc-hexane, mp 107. A suspension of crude 17 (256 mg), 4-(4-fluorobenzoyl)piperidine hydrochloride (244 mg, 1 mmol), NaHCO 3 (336 mg, 4 mmol) and NaI (300 mg, 2 mmol) in CH 3 CN (15 ml) was stirred under reflux for 15 h. The work-up and purification was performed in a similar manner to that described in method E to afford 18b (335 mg, 78% overall) as colorless crystals. The physical data for 18b are listed in Table 7 . -1-methyl-1,4,5,6,7,8-hexahydropyrrolo[3,2-c] azepin-4-one (15) A solution of 14a (797 mg, 2 mmol) and hydroxylamine hydrochloride (556 mg, 8 mmol) in pyridine (40 ml) was stirred at 90°C for 17 h. After the reaction mixture was evaporated to dryness, the residue was diluted with half-saturated K 2 CO 3 (80 ml), and then extracted with CHCl 3 (2ϫ100 ml). The combined extracts were washed with brine, dried, and concentrated to give an oil, which contained mainly 15 (Rf 0.46, CHCl 3 : MeOHϭ9 : 1) and a trace amount of the isomer 15Ј (Rf 0.35, CHCl 3 : MeOHϭ9 : 1). The mixture was subjected to column chromatography (eluent, CHCl 3 : MeOHϭ19 : 1) to give (E)-oxime 15 (816 mg, 99%) as a colorless oil from the first fraction. The second fraction yielded (Z)-oxime 15Ј (11 mg, 1%) -[3-[4-(4-Fluorophenyl)piperazin-1-yl]propyl]-1-methyl-1,4,5,6,7,8-hexahydropyrrolo[3,2-c]azepin-4-one-8-spiro-2-(1,3 -dithiolane) Dihydrochloride (16) To a stirred solution of 14a (398 mg, 1 mmol) and 1,2-ethanedithiol (168 ml, 2 mmol) in acetic acid (15 ml) was added dropwise boron trifluoride etherate (246 ml, 2 mmol), followed by stirring at room temperature. After 24 h, 1,2-ethanedithiol (1.5 ml, 18 mmol) and boron trifluoride etherate (1.97 ml, 18 mmol) were added and the resultant mixture was stirred for an additional 48 h. The reaction mixture was then made basic with 2 N NaOH and extracted with CHCl 3 (2ϫ50 ml). The combined extracts were washed with brine, dried, and concentrated. The residue was purified by column chromatography (eluent, EtOAc : (20 ml) was added a saturated solution of hydrogen chloride in CHCl 3 (120 ml) at room temperature, and stirring was continued at room temperature for 2 h. The mixture was washed with saturated NaHCO 3 (100 ml) and brine (50 ml), dried and concentrated. , 10% Pd-C (50 mg) and acetic acid (5 drops) in EtOH (30 ml) was vigorously stirred under an atmosphere of hydrogen at room temperature for 20 h. The catalyst was filtered through celite and washed with CHCl 3 . After the combined filtrate and washings were concentrated, the residue was diluted with NaHCO 3 (50 ml) and extracted with CHCl 3 (3ϫ50 ml). The extracts were washed with brine, dried, and concentrated to give an oil, which was purified by column chromatography (eluent, EtOAc To a warm solution of racemic 18a (20.0 g, 50 mmol) in MeOH (160 ml) was added L-(ϩ)-tartaric acid (7.50 g, 50 mmol). After the mixture was stirred at room temperature overnight and then at 0°C for 1 h, the precipitate was collected and dried, yielding 12.5 g of a colorless powder. 2 N NaOH (56.5 ml, 113 mmol) was added to this solid, and extracted with CHCl 3 (3ϫ100 ml). The extracts were washed with brine, dried, and evaporated to give the (Ϫ)-rich free form. The operations described above, i.e. formation of a salt with L-(ϩ)-tartaric acid (1 eq), collection of precipitate, neutralization, extraction and evaporation, were repeated once more. The obtained solid was recrystallized from 2-propanol (IPA) (1 ml/1 g-solid) three times to afford optically pure (Ϫ)-18a (5.78 g, 29%, 99.4% ee). The filtrate from the first precipitate was concentrated and converted to the free base to give 10.2 g of (ϩ)-rich free form as a colorless solid. The operations described as for (Ϫ)-18a, i.e. formation of a salt with D-(Ϫ)-tartaric acid (1 eq), collection of precipitate, neutralization, extraction and evaporation, were repeated three times. The obtained solid was recrystallized from IPA (1 ml/1 g-solid) twice to afford optically pure (ϩ)-18a (5.36 g, 27%, 99.5% ee 
Method F: 5-[2-[4-(4-Fluorophenyl)piperazin-1-yl]ethyl]-1-methyl-

Method H: 5-[3-[4-(4-Fluorobenzoyl)piperidino]propyl]-8-hydroxy-1-
X-Ray Crystallographic Analysis of (؊)-18a · L-(؉)-Tartrate
Diffraction measurements were performed on a Rigaku AFC-7R diffractometer using graphite monochromated CuK a radiation (lϭ1.54178 Å). Crystals of (Ϫ)-18a · L-(ϩ)-tartrate were subjected to crystallographic analysis and were found to belong to the orthorhombic space group P2 1 2 1 2 1 with the following unit cell parameters; aϭ18.828(4) Å, bϭ18.829(5) Å, cϭ7.490(6) Å, Vϭ 2655(2) Å 3 , Zϭ4. The final R-factor and weighted R-factor were 0.048 and 0.072, respectively, based on 1765 reflections with IϾ3s (I).
Serotonin (5-HT 2 )-and a a 1 -Adrenergic-Receptor Antagonist Activity The functional serotonin (5-HT 2 )-and a 1 -adrenergic-receptor antagonist activities against serotonin and NE, respectively, were determined in the isolated guinea pig mesenteric artery and aorta, respectively. 13) Briefly, male Hartley strain guinea pigs were anesthetized with pentobarbital Na (50 mg/kg, i.p.) and killed by decapitation. The mesenteric arterial bed and aorta were rapidly dissected out. Helical strips (2 mm in width, 20 mm in length) of the arteries were prepared using forceps and mounted vertically in a Magnus chamber, filled with warm (37°C) and oxygenated (95% O 2 and 5% CO 2 gas mixture) Tyrode's solution with the following composition (in mM): NaCl 137, KCl 5.4, CaCl 2 2.7, MgCl 2 0.5, NaHPO 4 0.45, NaHCO 3 11.9, glucose 5.5. The upper side of the tissue was connected to a force-displacement transducer (Shinkoh U gage, UL-10G) using silk thread. The isometric tension was recorded continuously using a pen-recorder (National, VP-6537). After a 1-h equilibration period with a resting tension of 0.5 g, the mesenteric arterial or aortic preparation was contracted transiently with serotonin (10 Ϫ5 M) or continuously with NE (10 Ϫ5 M), respectively. Test samples at final concentrations of 10 Ϫ9 and 10 Ϫ6 M were added before transient contraction induced by serotonin or under continuous contraction induced by NE. The functional serotonin (5-HT 2 )-or a 1 -antagonist activities against serotonin or NE were determined as the reduction in peak contraction.
For selected compounds, the pA 2 values were determined to measure the potency of their antagonistic action against 5-HT 2 -or a 1 -receptors. Briefly, cumulative concentration-response curves for serotonin and NE were constructed by stepwise addition of the agonist, using helical strips of isolated femoral or mesenteric guinea pig arteries, respectively. Serotonin or NE was then washed out several times during a 1-h period. The strips were incubated with various concentrations of compounds for 10 min, and a concentrationresponse curve for serotonin or NE was obtained again. The pA 2 values were determined from Schild plots.
Receptor Binding Assays 5-HT 2 receptor, 22) a 1 -adrenoceptor, 23) 5-HT 1A receptor, 24) a 2 -adrenoceptor, 25) b-adrenoceptor, 26) D 2 -dopamine receptor, 27 ) mACh receptor, 28) H 1 -histamine receptor 29) and H 2 -histamine receptor 30) binding assays were performed as previously described with slight modifications. 3 H]pyrilamine and various concentrations of test compounds in 50 mM Na-K-phosphate buffer (pH 7.5) with a final incubation volume of 250 ml. Specific binding was defined as that displaceable by 2 mM triprolidine.
5-HT
H 2 -Histamine Receptor Binding Assay Aliquots (310 mg of protein) of guinea pig cerebral cortex membranes were incubated at 25°C for 30 min with 3 nM [ 3 H]tiotidine and various concentrations of test compounds in 50 mM Na-K-phosphate buffer (pH 7.5) with a final incubation volume of 250 ml. Specific binding was defined as that displaceable by 100 mM cimetidine.
For all binding assays, incubation was terminated by rapid filtration under vacuum, and the filters were processed for radioactivity determination. The inhibition of binding by the test compound was analyzed to estimate the IC 50 (the concentration of the test compound causing 50% inhibition of binding) using Multicalc™ Advanced (wallac, Finland).
Measurement of Platelet Aggregation
The platelet donors were five healthy volunteers aged 25-35 years who took no medication that might alter platelet function for at least two weeks before the start of the study. Canine platelets were prepared from six adult Beagle dogs. Venous blood was mixed with a one-tenth volume of trisodium citrate (0.1 M, pH 7.35), and PRP was then obtained by centrifugation at 200ϫg for 5 min at room temperature. It was adjusted to a platelet count of about 300000 ml Ϫ1 with autologous platelet-poor plasma, prepared by centrifugation at 900ϫg for 20 min. Platelet aggregation was measured by turbidometry in two dual-chamber channel platelet aggregometers (Mevanix, PAM-8C). PRP (200 ml) was incubated in the aggregation cuvette for 2 min with test sample (10 Ϫ9 -10 Ϫ5 M) and CaCl 2 (1 mM). Serotonin (1 or 10 mM) in combination with collagen (0.03-1 mg/ml) or ADP (0.3-2 mM) was then added. The final volume of PRPϩagonist/test samples was 250 ml. The concentration of serotonin was chosen because it produced a submaximal potentiation effect, and when used alone it caused less than 10% aggregation. The concentrations of collagen and ADP were determined in each preparation as the maximum concentrations that caused less than 10% aggregation. The degree of aggregation at 10 min after the addition of agonists was measured as the percentage of the difference in light transmission between PRP and platelet-poor plasma.
Acute Pulmonary Thromboembolic Death in Mice Male ddY mice weighing about 25 g (5 to 6 weeks-old) were used after overnight fasting. Acute pulmonary thromboembolism was induced by rapid injection of a mixture (0.1 ml/10 g body weight) of serotonin (1 mg/kg) and collagen (5 mg/kg) into the tail vein and the mortality of mice within 10 min was determined. With the exception of sarpogrelate, all compounds were dissolved in saline containing 10% dimethylsulfoxide. Sarpogrelate was dissolved in 0.5% tragacanth in water according to Hara et al. 31) Compounds were administered orally one hour prior to the injection of serotonin and collagen. Twenty mice were used for each group. Results are expressed as mortality rate in animal numbers and percentage. The dose (ED 50 ) producing 50% reduction of mortality was estimated from the dose-response curve.
